< Helmut Zarbl Ph.D. EOHSI Directory | EOHSI


Helmut Zarbl Ph.D.

EOHSI Director – Professor – NIEHS Center Director Rutgers University- School of Public HealthEOHSI – Toxicology
Work EOHSI Room 218 170 Frelinghuysen Rd Piscataway New Jersey 08854 Work Phone: 848-445-2354 Work Fax: 732-445-4161
Photo of Helmut Zarbl Ph.D.

Biographical Info

Dr. Zarbl serves as the Director of the NIEHS sponsored Center for Environmental Exposures and Disease. He is also the Associate Director For Public Health Sciences at the Cancer Institute of New Jersey. He serves on numerous national research review and advisory panels, and editorial panels.. Dr. Zarbl is known for his work in areas of toxicogenomics, and mechanisms of and genetic susceptibility to chemical carcinogenesis, mechanisms of mutagenesis and toxicity, and technology development. These research efforts have to date resulted in over 70 scientific papers and book chapters.

Research Areas

Research has focused largely on toxicogenomics and functional genomics, carcinogenesis, molecular and cellular biology, and toxicology. Specifically this has included work understand to molecular mechanisms of chemical carcinogenesis and the genetic basis for differential susceptibility to mammary carcinogenesis using animal and in vitro model systems, and then translating the findings to human breast cancer.

Research Highlights

Studies in the rat model have included analysis of oncogene activation, mechanisms of signal transduction, and genetic linkage analysis to identify mammary tumor suppressor genes. He has also used toxicogenomics to dissect mechanisms of mechanism carcinogenesis, tumor progression and chemoprevention. His studies in the area of toxicogenomics include the development and application of standards for DNA microarray experiments, and phenotypic anchoring of response of human cells, model organisms (yeast) and target organs (rodents) to toxicants, providing insights into dose and temporal responses, as well as mechanisms of action. He is also actively involved in technology development for functional genomics and biomarker screening.

Recent Publications

  1. Fröhlich, A, Sirokay, J, Fietz, S, Vogt, TJ, Dietrich, J, Zarbl, R, Florin, M, Kuster, P, Saavedra, G, Valladolid, SR et al.. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. EBioMedicine. 2020;59 :102962. doi: 10.1016/j.ebiom.2020.102962. PubMed PMID:32861198 PubMed Central PMC7475111
  2. Hoffmann, F, Zarbl, R, Niebel, D, Sirokay, J, Fröhlich, A, Posch, C, Holderried, TAW, Brossart, P, Saavedra, G, Kuster, P et al.. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clin Epigenetics. 2020;12 (1):94. doi: 10.1186/s13148-020-00883-9. PubMed PMID:32586358 PubMed Central PMC7318478
  3. de Vos, L, Grünwald, I, Bawden, EG, Dietrich, J, Scheckenbach, K, Wiek, C, Zarbl, R, Bootz, F, Landsberg, J, Dietrich, D et al.. The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas. Epigenetics. 2020; :1-18. doi: 10.1080/15592294.2020.1754675. PubMed PMID:32281488
  4. Klümper, N, Ralser, DJ, Bawden, EG, Landsberg, J, Zarbl, R, Kristiansen, G, Toma, M, Ritter, M, Hölzel, M, Ellinger, J et al.. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. J Immunother Cancer. 2020;8 (1):. doi: 10.1136/jitc-2020-000552. PubMed PMID:32234847 PubMed Central PMC7174079
  5. Fröhlich, A, Loick, S, Bawden, EG, Fietz, S, Dietrich, J, Diekmann, E, Saavedra, G, Fröhlich, H, Niebel, D, Sirokay, J et al.. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine. 2020;52 :102647. doi: 10.1016/j.ebiom.2020.102647. PubMed PMID:32028068 PubMed Central PMC6997575
  6. Liu, Y, Chen, X, Gong, Z, Zhang, H, Fei, F, Tang, X, Wang, J, Xu, P, Zarbl, H, Ren, X et al.. Fry Is Required for Mammary Gland Development During Pregnant Periods and Affects the Morphology and Growth of Breast Cancer Cells. Front Oncol. 2019;9 :1279. doi: 10.3389/fonc.2019.01279. PubMed PMID:31824855 PubMed Central PMC6881260
  7. Green, AL, Eid, A, Zhan, L, Zarbl, H, Guo, GL, Richardson, JR. Epigenetic Regulation of the Ontogenic Expression of the Dopamine Transporter. Front Genet. 2019;10 :1099. doi: 10.3389/fgene.2019.01099. PubMed PMID:31749842 PubMed Central PMC6844290
Search PubMed
Categories: Faculty, Toxicology, Member
Updated 3 months ago.
Skip to toolbar